Search

This study aimed to investigate the protective effects of Naringin in Cyclophosphamide (CYP)-induced cardiotoxicity in rats. In the study, forty male adult Sprague Dawley rats weighing approximately 200-250 g were used. Rats were divided into 5 experimental groups as control, CYP, Naringin50+CYP, Naringin100+CYP and Naringin100. Control and CYP groups were administered to intragastric (i.g.) saline for 10 days. Also, the CYP group was given a single dose of CYP (200 mg/kg, intraperitoneal (i.p.)) on the 10th day. Naringin50+CYP and Naringin100+CYP groups were administered i.g. 50 and 100 mg/kg doses of Naringin for 10 days, respectively, and was given a single dose of CYP (200mg/kg, intraperitoneal (i.p.)) on the 10th day. Naringin100 group was administered to Naringin (100mg/kg), i.g.) for 10 days. ECG was recorded under anesthesia, and intracardiac blood samples were taken. Troponin I, creatine kinase (CK) and creatine kinase-MB (CK-MB) parameters were examined in serum samples. As a result of the necropsy, preparations were prepared by routine cardiac tissue follow-up method for histopathological examination. For the detection of DNA damage in the cardiac tissue, 8-OHdG expression was investigated. CYP has been shown to have cardiotoxic effects on ECG values, cardiac enzymes, and cardiac histopathology of rats. In this study, it was determined that Naringin has a protective effect in CYP-induced cardiotoxicity in rats. [ABSTRACT FROM AUTHOR]